- Home
- IRMD vs CGEM Comparison
IRMD vs CGEM Comparison
Compare IRMD & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRMD
- CGEM
- Stock Information
- Founded
- IRMD 1992
- CGEM 2016
- Country
- IRMD United States
- CGEM United States
- Employees
- IRMD N/A
- CGEM N/A
- Industry
- IRMD Medical/Dental Instruments
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- IRMD Health Care
- CGEM Health Care
- Exchange
- IRMD Nasdaq
- CGEM Nasdaq
- Market Cap
- IRMD 618.5M
- CGEM 730.2M
- IPO Year
- IRMD 2014
- CGEM 2021
- Fundamental
- Price
- IRMD $54.20
- CGEM $11.20
- Analyst Decision
- IRMD Strong Buy
- CGEM Strong Buy
- Analyst Count
- IRMD 1
- CGEM 7
- Target Price
- IRMD $60.00
- CGEM $31.67
- AVG Volume (30 Days)
- IRMD 43.3K
- CGEM 512.5K
- Earning Date
- IRMD 02-06-2025
- CGEM 11-07-2024
- Dividend Yield
- IRMD 1.12%
- CGEM N/A
- EPS Growth
- IRMD 13.16
- CGEM N/A
- EPS
- IRMD 1.46
- CGEM N/A
- Revenue
- IRMD $71,305,130.00
- CGEM N/A
- Revenue This Year
- IRMD $13.29
- CGEM N/A
- Revenue Next Year
- IRMD $10.76
- CGEM N/A
- P/E Ratio
- IRMD $36.62
- CGEM N/A
- Revenue Growth
- IRMD 13.23
- CGEM N/A
- 52 Week Low
- IRMD $40.18
- CGEM $8.49
- 52 Week High
- IRMD $57.95
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- IRMD 46.78
- CGEM 30.23
- Support Level
- IRMD $51.75
- CGEM $12.30
- Resistance Level
- IRMD $56.50
- CGEM $12.79
- Average True Range (ATR)
- IRMD 1.41
- CGEM 0.62
- MACD
- IRMD -0.26
- CGEM -0.03
- Stochastic Oscillator
- IRMD 24.11
- CGEM 2.96
About IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.